Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12 | $9 | $11 | $7 |
| - Cash | $1 | $0 | $1 | $2 |
| + Debt | $1 | $1 | $2 | $1 |
| Enterprise Value | $12 | $10 | $12 | $6 |
| Revenue | $2 | $1 | $1 | $1 |
| % Growth | 53% | 33.3% | 32.9% | – |
| Gross Profit | $2 | $1 | $1 | $1 |
| % Margin | 83.2% | 87.9% | 85% | 86.2% |
| EBITDA | $0 | -$0 | -$1 | -$0 |
| % Margin | 17.5% | -35.3% | -62.4% | -45.2% |
| Net Income | $0 | -$1 | -$1 | -$0 |
| % Margin | 12.4% | -43.1% | -75.4% | -59.7% |
| EPS Diluted | 2.34 | -5.8 | -8.03 | -5.15 |
| % Growth | 140.3% | 27.8% | -55.9% | – |
| Operating Cash Flow | -$0 | -$1 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$1 | -$0 | -$0 |